Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study. A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results